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Abstract. Vitronectin endows plasminogen activator
inhibitor 1 (PAI-1), the fast-acting inhibitor of both tis-
sue-type plasminogen activator (t-PA) and urokinase-
type plasminogen activator (u-PA), with additional
thrombin inhibitory properties. In view of the apparent
association between PAI-1 and vitronectin in the endo-
thelial cell matrix (ECM), we analyzed the interaction
between PAI-1 and thrombin in this environment. Upon
incubating 'III-labeled a-thrombin with endothelial cell
matrix (ECM), the protease formed SDS-stable com-
plexes exclusively with PAI-1, with subsequent release
of these complexes into the supernatant. Vitronectin
was required as a cofactor for the association between
PAI-1 and thrombin in ECM. Metabolic labeling of
endothelial cell proteins, followed by incubation of
T
HE activation of plasminogen is a key step both in
the fibrinolytic system and in various physiological
and pathophysiological processes, involving extra-
cellular matrix degradation (e.g., inflammatory reactions,
malignant invasion and metastasis, ovulation, nidation, cell
migration and tissue remodeling) (for review see Dano et al.,
1985). Therefore, theprecise regulation ofplasminogen acti-
vation with respect to time and location is of critical impor-
tance for the organism. A major physiological mechanism
for the control of plasminogen activation is provided by the
action of plasminogen activator inhibitor 1 (PAI-1),' the
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ECM with t-PA, u-PA, or thrombin, indicated that all
three proteases depleted PAI-1 from ECM by complex
formation and proteolytic cleavage. Proteolytically in-
active thrombin as well as anticoagulant thrombin, i.e.,
thrombin in complex with its endothelial cell surface
receptor thrombomodulin, did not neutralize PAI-1,
emphasizing that the procoagulant moiety of thrombin
is required for a functional interaction with PAI-1. A
physiological implication of our findings may be re-
lated to the mutual neutralization of both PAI-1 and
thrombin, providing a new link between plasminogen
activation and the coagulation system. Evidence is
provided that in ECM, procoagulant thrombin may pro-
mote plasminogen activator activity by inactivating
PAI-1.
fast-acting inhibitor of tissue-type plasminogen activator
(t-PA) and urokinase-type plasminogen activator (u-PA) (for
review see Schleef and Loskutoff, 1988) . Recently, consid-
erable support for the role of PAM in prevention of tumor-
mediated extracellular matrix degradation has been reported
(Cajot et al., 1990). These investigators showed, using co-
culture experiments, that a PAI-1-expressing cell couldabro-
gate the invasive property of another cell type.
During the past few years, numerous studies have revealed
important biochemical and cell biological data on PAM.
Molecular cloning of full-length PAI-1 cDNA and elucida-
tion of its nucleotide sequence has predicted the amino acid
sequence of the protein. These studies showed that the inhib-
itor belongs to the serine protease inhibitor ("serpin") super-
family of proteins (Ny et al., 1986; Pannekoek et al., 1986;
Ginsburg et al., 1986; Andreasen et al., 1986b). A serpin
functions by acting as a pseudo-substrate and traps the en-
zyme by forming a 1:1 equimolar, SDS-resistant, inactive
complex (Travis and Salvesen, 1983; Huber and Carrell,
1989) . The relevance of a serpin-protease interaction is de-
termined by (a) their appearance in the same compartmentor cell type, (b) their concentrations in that compartment,
and (c) their association rate. The latter parameter may be
affected by cofactors, such as glycosaminoglycans, that
significantly accelerate the interaction between the serine
protease thrombin and the serpins antithrombin III (Rosen-
berg and Damus, 1973), heparin cofactor II (Tollefsen and
Blank, 1981), and protease nexin I (Baker et al., 1980).
PAM is synthesized and secreted by cultured, vascular en-
dothelial cells (Loskutoffand Edgington, 1977) and a large
number ofcell lines (e.g., the human fibrosarcoma cell line
HT-1080 [Andreasen et al., 1986a]) . Moreover, it has been
reported that PAM is deposited in the subcellular matrix of
a variety ofculturedcells, including humanendothelial cells,
fibroblasts, and sarcoma cells(Laiho et al., 1986; Rheinwald
et al., 1987; P611anen et al., 1987; Levin and Santell, 1987),
a finding that indicates the potential for efficient control of
plasminogen activation in the growth substratum of these
cells. Recently, it was shown that PAM is associated with its
binding protein vitronectin in plasma, in the subcellular ma-
trix of endothelial cells (ECM), and in platelets (Wiman et
al., 1988; Declerck et al., 1988; Mimuro and Loskutoff,
1989; Preissner et al., 1989; Salonen et al., 1989). At least
for cultured vascular endothelial cells, vitronectin in the
ECM is sequestered from the serum-containing growth me-
dium and shown to be a requirement for PAI-1 deposition in
the ECM (Seiffert et al., 1990; Preissner et al., 1990). In
vivo, the presence of vitronectin in the vessel wall is un-
disputed, but its origin has not been established (Guettier et
al., 1989; Niculescu et al ., 1989) . It should be notedthat in
vivo vitronectin may be sequestered from the serum as well
or, alternatively, synthesized by cells constituting the vessel
wall.
Recently, we reported that vitronectin endows PAI-1 with
an additional specificity for thrombin and increases the
second-order association rate constant with this protease by
abouttwo orders ofmagnitude (Ehrlich et al., 1990). In con-
trast, we confirmed that vitronectin does not alter the rate
constant of PAI-1 with its target protease t-PA (Declerck et
al., 1988). These findings together with the aforementioned
considerations prompted us to study the interaction of
thrombin with the authentic ECM of cultured endothelial
cells. Consequently, we investigated whether PAM, depos-
ited in the ECM and colocalized with vitronectin (Mimuro
and Loskutoff, 1989), would be the "target" of thrombin.
Here, we demonstrate that, upon administration of proco-
agulant thrombin to ECM, serpin-typical, SDS-resistant
complexes are generated exclusively with PAM and that
vitronectin is required as a cofactor for this interaction.
Procoagulant thrombin depletes PAM from ECM via com-
plex formation and proteolytic cleavage, thereby promoting
the activity ofplasminogen activators. In the fibrinolytic sys-
tem, it has been recognized that thrombin indirectly en-
hances t-PA-induced plasminogen activation by the genera-
tion of fibrin, the obligatory cofactor for the enzyme (for
review see Collen, 1980) . In this report, we provide evi-
dence for yet another pathway of thrombin-mediated promo-
tion of plasminogen activator activity; i.e., by specific neu-
tralization of ECM-associated PAI-1.
Materials andMethods
Materials
[35SIMethionine (in vivo cell-labeling grade) and `I-Na were purchased
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from Amersham International PLC (Amersham, U. K.). The chromogenic
substrates H-1}isoleucyl-L-prolyl-L-arginine-p-nitroanilide-dihydrochloride
(S2288) and H-D-phenylalanyl-L-pipecolyl-L-argininep-nitroanilide-dihy-
drochloride (S2238) were obtained from KabiAB (Stockholm, Sweden).
Hirudin, BSA, diisopropyl fluorophosphate, the active site titrant p-nitro-
phenyl p'-guanidinobenzoate, and heparin from porcine intestinal mucosa
were from Sigma Chemical Co. (St. Louis, MO). QAE-Sephadex and cy-
anogen bromide-activated Sepharose 4B was from Pharmacia Fine Chemi-
cals (Uppsala, Sweden).
Purified Proteins
The concentration of purified human a-thrombin (4.5 mg/ml) was deter-
mined as described (Bradford, 1976) . Active site titration of a-thrombin
withp-nitrophenylp'-guanidinobenzoate (Chase and Shaw, 1970) indicated
a concentration of5.0 mg/ml, a value which was usedthroughout the experi-
ments. Radioiodination of thrombin (25 pg) with 125I-Na (1 mCi) was per-
formed using the Iodogen method and resulted in a specific activity of 30
ACi/pg protein. 1251-labeledthrombin comigrated with unlabeled thrombin
on SDS-polyacrylamide gels and retained (a) its catalytic activity towards
52238 and (b) its ability to rapidly form SDS-resistant complexes with an-
tithrombin III in the presence of0.5 U/ml heparin (Ehrlich et al., 1991).
Two-chain Bowes melanoma t-PA(910,000 U/mg) was purchased from Bio-
pool (Umea, Sweden). High molecular weight u-PA, purified from human
urine, was from Calbiochem Corp., (La Jolla, CA). Thrombomodulin was
purified to apparent homogeneity from rabbit lungs as described (Galvin et
al., 1987). Briefly, the homogenates were extracted with Triton X-100 and
adsorbed on QAE-Sephadex. The active fractions were pooled and im-
munopurified on immobilized antithmmbomodulin antibody, followed by
chromatography onDIPthrombin-Sepharoseand, finally, by Mono Q chro-
matography.
Antisera
The murine monoclonal antibodies CLB-IC3 and CLB-IB10, directed
againsthumanPAI-1 werea gift from Dr. J. A. van Mourikand Dr. H. Lam-
bers (Department of Blood Coagulation, CLB Amsterdam). Additional
monoclonal anti-human PAI-1 antibodies (MAI-12 and Sepharose-coupled
MAI-13) were purchased fromBiopool. Murine monoclonal antibody CLB-
t-PA-6, directed against "kringle 1" of t-PA, was prepared and mapped as
described (Van Zonneveld et al., 1986). Murine monoclonal antibodies
aATRI-24, directed against human antithrombin III, and URO-4, directed
against human u-PA, were the kind gift of Dr. Janny Abbink and Jan-Paul
de Boer from the Department of Autoimmune Diseases (CLB, Amsterdam).
Polyclonal antisera againstpurified human vitronectinwere raised inrabbits
(Ehrlich et al., 1990) and were fractionatedby ammoniumsulphateprecipi-
tation and ion-exchange chromatography on DEAE-Sephacel. Immuno-
globulins from a control rabbit thathad not been immunized were prepared
in an identical fashion.
Rabbit immunoglobulins, raised against purified human von Willebrand
factor, were from DAKOPATTS (Copenhagen, Denmark).
Preparation ofDishes Coated with ECM
ofCultured HUVECs
Human umbilical vein endothelial cells (HUVECs) were isolated and cul-
tured in 75-cm2 flasks as described (Jaffe et al., 1973; Willems et al.,
1982). Second- or third-passage HUVECs were grown in 6-well plates or
25-cm2 flasks until they reached confluency. 2-3 d later, the cells were re-
moved as follows. The cells were washed three times with PBS (2 ml/well
per wash or 10 ml/flask per wash) and then incubated for 10 min at 20°C
with PBS containing 0.5 % (vol/vol) Triton X-100 to remove the cells. The
remaining ECM was washed three times with PBS and, additionally, twice
with TST (20 mM Tris-HCI, pH 7.4, containing 100 mM NaCl and 0.1%
[vol/vol] Tween-80). After this treatment, no visible cell debris was left in
the wells as judged by light microscopy.
ComplexFormationbetween 18IThrombin
andECMProteins
"'I-labeled human a-thrombin (final concentration: 0.3 nM) in TST was
incubated with ECM at 20°C on a horizontal rotating platform (25 rpm).
At designated times, ranging from 2.5 to 60 min, the supernatant was re-
moved. Both the supernatant and (SDS-dissolved) ECM were separately
subjected to 10% (wt/vol) SDS-PAGE. In some experiments, the ECM was
1774Figure 1. Time course of
the appearance of SDS-sta-
ble complexes between 1251-la-
beled thrombin and a protein
fromECM . 1z5I4abeled throm-
bin (0.3 W) was incubated
in TNT buffer with ECM .
At time points indicated, su-
pernatant was removed from
ECM and analyzed by SDS-
PAGE and autoradiography .
preincubated for 15 min at 20°C with different antibodies on a horizon-
tal rotating platform (25 rpm), before the addition of the radiolabeled
thrombin.
Metabolic Labeling ofECMProteins
HUVECs, grown to confluency in 25-cm2 flasks, were incubated for 2 h
at 37°C with 2 nil ofglutarnine- and methionine-deficientRPMI 1640, sup-
plemented with transferrin (0.02 mg/ml), insulin (0.01 mg/ml), human se-
rum albumin (5.0 mg/ml), glutantine (0.3 mg/ml), and [ 35S]methionine (10
jXi/ml ; specific activity >1,000 Ci/mmol) . Then, unlabeled L-methionine
was added (final concentration : 50mM) for achase period of30 min, after
whichthecells were removedasdescribed above. PAI4 representedthe pre-
dominant radiolabeled protein band in the matrix (data not shown) .
Interaction oft-PA, u-PA, and Thrombin with
MetabolicallyLabeledPAI-1fromECM
After detergent-induced removal of HUVECs, the proteases were added to
the supernatant (TSTbuffer) ofmetabolically labeledECM . Incubation was
carried out at 20°C for various times and terminated by removal of the su-
pernatants from the culturedishes . Aliquots ofthese supernatants were then
immunoprecipitated with the appropriate antibodies coupled to Sepharose,
and the immunoprecipitable fractions were analyzed by SDS-PAGE and
fluorography as described below.
SDS-PAGE
Electrophoretic separationof polypeptides was performed using 10% poly-
acrylamide gels as described (Laemmli, 1970) . Samples were analyzed un-
der nonreducing conditions in 0.05 M Tris-HCI, pH 6.8, 2% (wt/vol) SDS,
8% (vol/vol) glycerol, and 0.01% (wt/vol) Bromophenol Blue, except when
indicated otherwise . The relative migration ofthe radiolabel was visualized
by autoradiography (for 1251) or fluorography (for 355) and compared with
the migrationofprestainedmolecular weight markers (GibcoLaboratories,
Grand Island, NY, Bethesda Research Laboratories, Gaithersburg, MD) .
Immunoprecipitation
Murine monoclonal antibodies, used forimmunoprecipitations as indicated
in the text, were coupled to cyanogen bromide-activated Sepharose 4B ac-
cording to the instructions provided by the manufacturer (10 mg protein/g
Sepharose) . The Sepharose beads were blocked by incubation for 2 hat 4°C
with 0.2 M glycine, pH 8.0, and stored at 4°C in PBS containing 0.04%
(wt/vol) sodium azide. Immobilized antibodies (25 Alofpacked beads) were
incubated 12-16 h with 75 Al of the respective sample . The beads were
washed three times with 1 ml TST buffer, followed by two washes with 1 ml
TST containing 500mM NaCl and, finally, with 1 ml TST buffer. Immuno-
precipitated proteins were solubilized in 50 pl gel sample buffer and 25 Al
was subjected to SDS-PAGE and, subsequently, to autoradiography or
fluorography.
InfluenceofECMon Amidolytic t-PA Activity
HUVECS (third passage) were plated into 96-well plates and grown to
confluency. Cells were removed with 0.5% (vol/vol) Triton X-100 as de-
scribed above, and 50 ld TST buffer containing 10 mg/ml BSA was added
to ECM in each well . The wells then received either no compound or the
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inhibitory monoclonal anti-PAI-1 antibody (MAI42, 8014g/ml) or throm-
bin (30 or 300 nM) and incubation was allowed to proceed for 30 min . The
supernatants were taken off; the wells were washed three times with 1 ml
TST buffer containing 10 mg/ml BSA; and 50 pl ofthis buffer containing
40 U/ml hirudin (to quench residual thrombin activity) was added to each
well . Then, 5 )z1oft-PA (final concentration : 3 nM) was addedintothe wells
containing the pretreated matrices. After a 30-min incubation, 25 pl ofthe
supernatants was added to 200 pl 0.5 mM S2288 and the optical density
at 405 nm was recorded every 3 min using a Titertek lwinreader (Flow
Laboratories, Irvine, U.K.) . The values of control incubations, without
added t-PA, were subtracted from the values of the respective samples .
Results
ComplexFormation between a Protein
fromECMand Thrombin
To study whether thrombin would form SDS-stable com-
plexes with any compound present in the ECM, 12514abeled
thrombinwas added toECM which remained attached to the
bottom of tissue culture flasks after removal of the en-
dothelial cells . After an incubation, ranging from 2.5 to 60
min, the supernatants as well as SDS-detached ECMs were
analyzed separately by SDS-PAGE and autoradiography .
Fig . 1 shows the time-dependent appearance in the superna-
tant ofECM of SDS-stable complexes between thrombin and
another protein . A faint complex band is visible after 2.5
min of incubation which, upon longer incubation, increases
in intensity and reaches optimal complex formation after
about 60 min . Free as well as complexed thrombin are al-
most exclusively (>95 %) recovered in the supernatant of
ECM (data not shown), indicating that (a) the large majority
of the thrombin does not bind to ECM and (b) after forma-
tion of the SDS-stable complex between thrombin and a
compound from theECM, the complex dissociates from the
ECM . The apparent molecular weight of the complex is
-80,000. This value corresponds with a 1 :1 equimolar com-
plexbetween thrombin and anECM protein with an apparent
molecular weight of -44,000. Clearly, the apparent molecu-
Figure 2 . Immunological identification oftheECM protein forming
SDS-stable complexes with 125I4abeled thrombin . Aliquots of the
supernatant of a 60 min incubation of 1251-labeled thrombin with
ECM were immunoprecipitated with the following murine mono-
clonal antibodies : (lane 1) MAI-13 (anti-PAI-1) ; (lane 2) CLB-1C3
(anti-PAI4) ; (lane 3) CLB-t-PA 6 (anti-t-PA) ; and (lane 4) aATIII-
24 (anti-antithrombin III) . Immunoprecipitable (A) and non-
precipitable (B) fractions were analyzed by SDS-PAGE and autora-
diography.
1775Figure 3 Effect ofmonoclonal
PAM antibodies onthe forma-
tion of SDS-stable complexes
between ' 251-labeled thrombin
and ECM-associated PAI-1 .
ECM was incubated with anti-
bodies (6jig/ml) againstPAI-1.
After 15 min, 1251-labeled
thrombin (0.3 mM) was add-
ed, and the incubation was al-
lowed to proceed for 60 min .
The supernatants were then
analyzed by SDS-PAGE and autoradiography. (Lane 1) No anti-
body ; (lane 2) CLB-1C3 ; pane 3) CLB-1B10 ; (lane 4) MAI-12 .
Three independent experiments gave similar results .
lar weight ofPAM, being a predominant protein in theECM,
would fit as the counterpart of thrombin in the observed
complex .
Identification oftheECMComponent
To assess whether the ECM compound forming serpin-
typical SDS-stable complexes with thrombin is identical to
PAM, part of the supernatant of a 60-min incubation of
121J_
labeled thrombin with ECM was immunoprecipitated with
two different monoclonal antibodies against PAM and, as a
control, with monoclonal antibodies against antithrombin III
and t-PA . The results are depicted in Fig . 2 . The SDS-stable
complexes can be quantitatively immunoprecipitated with
either one of the two monoclonal antibodies directed against
PAI-1 (lanes 1 and 2), whereas the control antibodies fail to
precipitate the complexes (lanes 3 and 4) . As expected, un-
complexed thrombin is not precipitated with any of the anti-
bodies . Consequently, thrombin forms complexes exclu-
sively with PAM present in the ECM .
Effect ofAnti-PAI1 Monoclonal Antibodies
on Complex Formation
Inhibition of the target enzymes t-PA and u-PA by PAW re-
quires the functionality of the carboxyl-terminally located
reactive center of the inhibitor. To establish whether the
same structural motifis implicated in the formation ofSDS-
stable complexes with thrombin, the experiments were car-
ried out in the presence of a monoclonal antibody (MAI-12)
that inhibits the interaction between PAI-1 and plasminogen
activators (Keijer et al ., 1991) . Noninhibitory anti-PAI-1
antibodies served as control . The results are shown in Fig .
3. Formation ofPAI-1-thrombin complexes is observed in the
absence of antibody (lane 1) . A preincubation ofECM for
15 min at 20°C with the noninhibitory antibodies CLB-1C3
and CLB-1B10 results in a similar extent of complex forma-
tion (lanes 2 and 3, respectively) . In contrast, preincubation
of ECM with the monoclonal anti-PAI-1 antibody MAI-12
completely abolishes the formation ofSDS-stable complexes
between thrombin and ECM-associated PAM, demonstrat-
ing the requirement ofa functionally reactive center for com-
plex formation with thrombin .
Effect ofAntivitronectin Antisera
on Complex Formation
In a purified system, the rate of interaction between PAI-1
and thrombin is greatly accelerated by the cofactor activity
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of vitronectin (Ehrlich et al., 1990) . Therefore, to further
characterize the interaction between thrombin and PAW in
the growth substratum of endothelial cells, the effect of a
polyclonal antiserum, raised against purified human vitro-
nectin, on the complex formation between thrombin and
PAI-1 was investigated . 1251-labeled thrombin was incubated
for 60 min with ECM that had been pretreated with an-
tivitronectin antiserum or with control antisera. As shown in
Fig . 4, preincubation ofECM with antivitronectin antiserum
(lane 2) resulted in a substantial decrease of complex forma-
tion as compared with the controls ; i.e., preincubation of
ECM in the absence of antisera (lane 1), a polyclonal antise-
rum againsthuman von Willebrand factor (lane 3), or preim-
mune serum from the rabbit used to generate the antivitro-
nectin antiserum (lane 4) . Thus, ECM vitronectin performs
an essential role to sustain complex formation betweenPAM
and thrombin .
Effect ofDifferent Proteases on ECM-associated
355-Labeled PAI1
Next, we studied the effect of thrombin on PAI-1, de novo
synthesized and deposited into the growth substratum, and
compared it with the effect of t-PA and u-PA . To that end,
the endothelial cells were metabolically labeled for 2 h with
['SS]methionine, followed by a chase period of 30 min .
Cells were then removed as described and the resulting
growth substrata were incubated for 1 h with increasing
amounts of either one of the unlabeled proteases thrombin,
t-PA or u-PA . During a 1-h incubation in the absence ofpro-
teases we observed a minor release of radiolabeled proteins
into the supernatant (data not shown) . As depicted in Fig .
5 one of these proteins, displaying an apparent molecular
weight of 44,000, is specifically immunoprecipitated with
the anti-PAI-1 monoclonal antibody MAI-13, indicating that
this protein is immunologically related to PAI-1 . In the pres-
ence of either t-PA, u-PA, or thrombin, the dose-dependent
appearance ofthree major immunoprecipitable polypeptides
can be noted . The two lower bands migrate at an identical
position with apparent molecular weights of 44,000 and
40,000, irrespective ofthe protease used . In contrast, the ap-
Figure 4. Effect of antivitro-
nectin antiserum on the forma-
tion of SDS-stable complexes
between 'ZSWabeled thrombin
and PAW . ECM was preincu-
bated with different antisera
(total protein : 22.5 ug/500
pl per well of a 6-well plate)
for 15 min, at which time
1251-
labeled thrombin was added,
and the incubation was allowed
to proceed for another 60 min.
The supernatants of the re-
spective incubations were ap-
pliedto SDS-PAGE and autora
diography. (Lane 1)No immunoglobulins ; pane 2 ) immunoglobu-
lins from a rabbit immunized with human vitronectin antiserum;
(lane 3) immunoglobulins from a rabbit immunized with human
von Willebrand factor antiserum; and pane 4) immunoglobulins
from a control (not immunized) rabbit . Three independent experi-
ments gave similar results.
1776parent molecular weight ofthe largest ofthe three bands was
strictly dependent on the protease used, being approximately
110,000 in the case of t-PA, 95,000 with u-PA, and 80,000
with thrombin . These findings, togetherwith the observation
that all three bands could be immunoprecipitated with the
anti-PAI-1 monoclonal antibody MAI-13, are consistent with
the notion that the indicated three bands represent three
different forms of PAI-1; i.e ., (from bottom to top) cleaved
inactive PAM, native PAM, and a complex ofPAM and the
respective protease . However, a striking difference can be
observed between the proteases with respect to the relative
quantities of complexed and cleaved PAI-1 . With u-PA, the
majority of PAI-1 eluted from ECM is in a serpin-typical,
SDS-resistant complex . However, with t-PA the amount of
cleaved PAI-1 approximates the amount ofPAM being in an
SDS-stable protease-protease inhibitor complex, whereas
with thrombin, the majority of the PAM eluted from ECM
is present in the cleaved, inactive form . It should be kept in
mind, that (part of) the 40,000-mol wt cleaved form ofPAI-1
Figure 5. Effect of proteases on ECM-
associated, "S-labeled PAI-1. ECM, met-
abolically labeled with [35S]methionine,
was incubated for 60 min with different
concentrations t-PA, u-PA, or thrombin
as indicated . Aliquots of the respective
supernatant were immunoprecipitated
with monoclonal antibody MAI-13 (anti-
PAI-1), and immunoprecipitable frac-
tions were subjected to SDS-PAGE and
fluorography .
may be generated from t-PA-PAI-1 or thrombin-PAI-1 com-
plexes by boiling the immunoprecipitates in SDS buffer be-
fore electrophoresis, an issue that will be dealt with in a fol-
lowing paragraph .
RequirementfortheProcoagulantActivity of
Thrombin to Deplete ECM-associatedPAM
Since a-thrombin can display either a procoagulant or an an-
ticoagulant activity, we determined the required properties
of the thrombin preparation to form complexes with PAI-1 .
For that purpose, thrombin was preincubated either with di-
isopropyl fluorophosphate, hirudin, or thrombomodulin .
After diisopropyl fluorophosphate treatment, <0.1% of the
thrombin remained amidolytically active towards the chro-
mogenic substrate S2238, whereas preincubation with
hirudin resulted in a residual amidolytic activity of <1%
(data not shown) . Thrombin in complex with rabbit throm-
bomodulin fully retained its amidolytic activity, however, the
Figure 6. Effect modulation ofthrombin activity on the interactionwith ECM-associated 35S-labeled PAI-1 . Metabolically labeled ECM was
incubated for 30 min with different concentrations of thrombin; DFP-treated thrombin (DFP-thrombin), hirudin-treated thrombin (HIR-
thrombin), or thrombin in complex with its endothelial cell surface receptor thrombomodulin (TM-thrombin) as indicated . Immunoprecipi-
table (monoclonal anti-PAI-1 antibody MAI-13) fractions of the respective supernatants were subjected to SDS-PAGE and fluorography .
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1777Figure 7 . Functional neutralization ofPAM activity inECM bypro-
coagulantthrombin . Metabolically labeled ECM was incubated for
60 min with the following concentrations of unlabeled thrombin :
0 nM panes 1) ; 3 nM (lanes 2) ; 30 nM (lanes 3) ; 300 nM (lanes
4) . The supernatants were removed and the matrices were washed
twice with TST buffer. Then, t-PA (A) or u-PA (B) to a concentra-
tion of30nM were added and incubated with the pretreatedECMs
for an additional 60 min, after which time the supernatants were
removed, immunoprecipitated with monoclonal anti-PAM anti-
body MAI-13, and subjected under reducing conditions to SDS-
PAGE and fluorography.
macromolecular specificity was shifted from procoagulant
to anticoagulant, as exemplified by efficient activation of hu-
man protein C (data not shown) . The results ofcomplex for-
mation of these four different thrombin preparations with
"S-labeled PAM, de novo synthesized and deposited in
ECM, are shown in Fig. 6. Consistent with the results
presented in Fig . 5, procoagulant thrombin effectively eluted
PAM from ECM, with a minor portion of the immunopre-
cipitable PAM being in an SDS-resistant complex with the
protease and the major fraction corresponding with the ap-
parent molecular weight of 40,000 of the cleaved form . In
contrast, none of the modified forms of thrombin eluted
PAM from ECM by complex formation and/or cleavage, in-
dicating that the procoagulant protease moiety of thrombin
is strictly required for specific complex formation and, con-
sequently, neutralization of PAM .
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Promotion ofPlasminogen ActivatorActivity inECM
by Procoagulant Thrombin
The effect of the interaction between thrombin and matrix-
associated PAI-1 on subsequent control ofplasminogen acti-
vation inECM was studied in two systems . In the first experi-
ment, metabolically labeled ECM was preincubated with
increasing concentrations of thrombin, followed by incuba-
tion with t-PA or u-PA and immunoprecipitation of the re-
spective supernatants, using antiprotease antibodies . The
results are shown in Fig . 7. If thrombin was absent during
the preincubation, both t-PA and u-PA eluted metabolically
labeled PAM from ECM by complex formation . In accord
with our previous observations, these complexes were al-
most completely SDS stable in the case of u-PA, whereas
with t-PA, approximately half of the radiolabeled PAM dis-
sociates from the complex during preparation of the sample
in gel loading buffer. However, after preincubating the ma-
trices with increasing amounts of thrombin, the number of
PAI-1-t-PA or PAI-1-u-PA complexes formed during subse-
quent incubation ofECM with these plasminogen activators
decreases in a dose-dependent manner.
A different experimental approach was used to show that
preincubation ofECM with thrombin neutralizes PAM ac-
tivity and thereby abrogates the capacity of ECM to inhibit
t-PA . To that end, ECM was preincubated with different
compounds as outlined below and the subsequent effect of
these pretreated ECM's on the activity of t-PA toward the
synthetic substrate S2288 was investigated . The results are
shown in Fig . 8. Incubation of t-PA with untreated ECM (A)
resulted in a 45% inhibition of the amidolytic activity as
compared with the control ; i.e., incubation of t-PA with
ECM with the monoclonal anti-PAI-1 antibody MA112 (B),
which inhibits the activity ofPAM . A similar effect as the
one observed with the antibody, i.e., prevention ofthe inhibi-
tory capacity of PAM, was seen upon preincubating ECM
with thrombin . A concentration of 30 nM resulted in partial
prevention of the inhibition executed by PAI-1 (C), whereas
with 300 nM of thrombin complete neutralization of PAM
was observed (D) .
150 200
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Figure 8. Effect ofthrombin on inhi-
bition oft-PA activity byECM . ECM
in 96-well plates, pretreated differently
as indicatedbelow, was incubated for
30 min with t-PA (3 nM) . Residual
t-PA activity in the wells was deter-
mined by adding aliquots to the chro-
mogenic substrate 52288 and record-
ing the increase of optical density at
405nm . Preincubationwas performed
for 30 min with buffer alone (A), in-
hibitory anti-PAW monoclonal anti-
body MAI-12 (B), 30 nM thrombin
(C), or 300 nM thrombin (D) . Ex-
periments were run in triplicate with
standard deviations of <5% .Discussion
In this report, we studied the functional interaction between
ECM-associated PAI-1 and exogenously added thrombin. For
this purpose, ECM formed by cultured human endothelial
cells was used. In this ECM, largely resembling the base-
ment membrane of the vessel wall with respect to composi-
tion and structure (Gospodarowicz et al., 1980; Vlodavsky
et al., 1980), PAI-1 is one of the abundant proteins, em-
phasizing the potential of this compartment for regulation of
events associated with protease activity. Administration of
'III-labeled procoagulant thrombin to ECM results in SDS-
resistant complexes between the protease and PAI-1 present
in ECM, followed by a rapid release ofthese complexes into
the supernatant. These observations are reminiscent of the
behavior of t-PA/PAI-1 complexes described in previous
studies (Barnathan et al., 1988; Schleef et al ., 1990) . Fur-
thermore, we demonstrate that depletion of PAI-1 from the
ECM by thrombin causes subsequentpromotion of the activ-
ity of a plasminogen activator, which may ultimately lead to
increased plasmin generation.
Formation of serpin-typical complexes between PAI-1 and
procoagulant thrombin in the growth substratum ofcultured
endothelial cellshas not been described previously. In an ex-
perimental approach similar to the one used here, Knudsen
et al. (1987) incubated I'll-labeled thrombin with the ma-
trix of bovine smooth muscle cells. Although PAI-1 is also
a predominant protein in the substratum of these cells, the
investigators did not observe SDS-resistant complexes be-
tween PAI-1 and thrombin. The apparent discrepancy with
our findings may be related to differences in the composition
of the matrices generated by these different cell types. In-
deed, as initially observed with purified components, the
efficient formation of thrombin-PAI-1 complexes is depen-
denton the presence ofcofactors such as vitronectin or hepa-
rin (Ehrlich et al., 1990, 1991). In agreement with these
findings, it was demonstrated that PAI-1 in the ECM is as-
sociated with its binding protein vitronectin (Preissner et al.,
1990; Seiffert et al., 1990) and that these complexes appear
to be essential also for maintenance of the adherent cell
phenotype as recently demonstrated for the humanfibrosar-
coma cell line HT1080 (Ciambrone and McKeown-Longo,
1990). The distribution and concentration of PAI-1-vitronec-
tin complexes may differ between substrata generated from
differentcell types and may explain differences in association
between thrombin and PAI-1.
A prerequisite for a functional interaction in vivo between
thrombin and PAI-1-vitronectin complexes in the suben-
dothelial structures is the accessibility ofthese complexes for
the protease. Endothelial cells are able to assemble the pro-
teases and cofactors of the coagulation system on their sur-
face, ultimately resulting in the generation of thrombin
(Stern et al., 1985). Thrombin can penetrate into suben-
dothelial layers not only when subendothelium is exposed to
the circulation, but also when the integrity ofthe endothelial
cell layer is maintained (Garcia et al., 1986). In view of the
morphological alterations of the endothelial cell monolayer,
observed upon administration of thrombin (Laposata et al .,
1983), it is conceivable that the subendothelial matrix is a
particularly susceptible target for thrombin. Having pene-
trated the endothelial cell monolayer, thrombin participates
in several physiological processes other than coagulation,
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notably proliferation and chemotaxis of inflammatory cells
as well as proteolytic degradation of basement membrane
proteins, leading to cell invasion and metastasis (Chen and
Buchanan, 1975; Bar-Shavit et al., 1983a,b; Bar-Shavit and
Wilner, 1986). Its critical involvement in such a variety
of physiological processes, together with the potentially
devastating effects on the organism resulting from excessive
proteolysis, requires rigorous regulation of the activity of
thrombin. In vivo, the procoagulant activity of thrombin is
controlled by two strikingly different mechanisms: (a) mod-
ulation of the macromolecular specificity ofthrombin by its
endothelial cell surface receptor thrombomodulin, turning
thrombin into an anticoagulant protein (Esmon, 1989) and
(b) inhibition of its activity by specific serpins (antithrombin
III [Rosenberg and Damus, 1973]), heparin cofactor II (Tol-
lefsen and Blank, 1981), and protease nexinI (Baker et al.,
1980). The reaction with these serpins is dramatically ac-
celerated by heparin . However, these regulatory factors and
cofactor may not be available or not operative at certain loca-
tions where thrombin can be found. For example, the endo-
thelial cells used in this study had been cultured in the pres-
ence of serum, containing for example antithrombin III; and
anticoagulantly active heparin-like glycosaminoglycans are
synthesized by endothelial cells (Marcum and Rosenberg,
1985). However, no complexes between thrombin and anti-
thrombin III-heparin were encountered in the present study.
This indicates that this serpin had not been sequestered from
the medium and/or heparin-like molecules are not deposited
in ECM. Rather, in this environment PAI-1-vitronectin com-
plexes may well serve as a unique regulatory system for
thrombin activity.
In addition to a role of PAI-1-vitronectin complexes in the
regulation of the degradation of basal membrane compo-
nents by serine proteases, it can be envisaged that such com-
plexes may provide a new link between coagulation and the
fibrinolytic system. Both systems are intimately connected at
the level of thrombin activity as evidenced by the present as
well as by several other observations. The influence of the
fibrinolytic system on coagulation is substantiated by the
finding that during thrombolytic therapy with t-PA, there is
a transient increase in thrombin in plasma (Owen et al.,
1988). This increase was speculated to be due to either the
initiation of the prothrombinase complex or to the release of
preexisting thrombin from the dissolving thrombus. The lat-
ter hypothesis might explain the high incidence of reocclu-
sion after successful coronary thrombolysis, considering the
high concentration ofthrombin in a thrombus (up to 140 nM;
Walz et al ., 1985) and the resistance of such fibrin-bound
thrombin to inhibition by antithrombin III-heparin (Hogg
and Jackson, 1989; Weitz et al ., 1990). Visa versa, thrombin
has the potential to affect the fibrinolytic system. Here, how-
ever, the situation appears to be more complex, since the
effect of thrombin on fibrinolysis may be in opposite direc-
tions; i.e., inhibition as well as stimulation. Inhibition by
thrombin may be related to (a) activation ofplatelets, result-
ing in the release of active PAI-1 (Erickson et al., 1984) and
of PAI-1-vitronectin complexes (Preissner et al., 1989), and
(b) increased release of PAI-1 from HUVECs (Gelehrter
and Szyncer-Laszuk, 1986; Grulich-Henn and Miiller-Berg-
haus, 1990). In vivo, elevated levels of active PAI-1 may
complex with the molar excess of plasma vitronectin and
may, presumably locally, affect the balance between t-PA ac-
1779tivity and that ofprocoagulant thrombin. Conversely, throm-
bin promotes fibrinolysis in several ways, e.g., by (a) indirect
stimulation of t-PA-mediated plasminogen activation by the
generation of fibrin, the obligatory cofactor of t-PA (for re-
view see Collen, 1980) and (b) stimulation of t-PA synthesis
in and release from (cultured) endothelial cells (Levin et al.,
1984). A similar observation has been made in vivo, using
experimental animals (Giles et al., 1989). Intravenous ad-
ministration ofmixtures, consisting ofactivated factor X and
phosphatidylcholine-phosphatidylserine, obviously causing
the generation ofthrombin, resulted in a rapid, almost 1,000-
fold increase in plasma levels of t-PA. In conclusion, there
is a variety of (partly opposite) effects that interconnect the
fibrinolytic system and coagulation. Specifically, the data
presented here are indicative of a direct interaction between
thrombin, the key enzyme in coagulation, and PAI-1, the ma-
jor protein controlling the activity of t-PA and u-PA. The ad-
dition of procoagulant thrombin to ECM, containing a high
local concentration of PAI-1-vitronectin complexes, results
in a mutual neutralization of both PAI-1 and thrombin. The
interaction between ECM-associated PAI-1-vitronectin com-
plexes and procoagulant thrombin constitutes an important
regulatory function for all subsequentprocesses that involve
thrombin-promoted, as well as plasminogen activator-pro-
moted, modification of the subendothelial matrix.
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